MetaCap

AbCellera Biologics (ABCL) vs Xeris Biopharma (XERS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AbCellera Biologics (ABCL) has outperformed Xeris Biopharma (XERS) over the past year, gaining 176.1% versus a gain of 148.5%. Over five years, XERS leads with a +682.0% price change compared with -30.7% for ABCL. AbCellera Biologics is the larger company by market cap ($3.16 billion vs $3.10 billion), about 1.0 times the size.

Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -194.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABCL+176.07%XERS+148.46%
+339%+150%-40%
Nov 21, 20251 yearNov 20, 2026
ABCL-38.67%XERS+647.58%
+684%+280%-124%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABCL versus XERS key metrics
MetricABCLXERS
Share price$9.69$16.97
Market cap$3.16B$3.10B
1-day change-7.45%+2.11%
YTD return+183.33%+116.18%
1-year return+176.07%+148.46%
5-year return-30.74%+682.03%
Forward P/E—63.64
EPS (TTM)$-0.48$-0.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.13M$291.85M
Revenue growth (YoY)+160.56%+43.72%
Net income (latest FY)$-146.41M$554.00K
Gross margin—85.41%
Operating margin-288.98%8.53%
Net margin-194.88%0.19%
52-week high$15.02$17.28
52-week low$2.75$5.25
Distance from 52-week high-35.46%-1.79%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+92.67%+1.89%
Average volume4.34M2.86M
Shares outstanding326.62M182.70M
Employees562435
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ABCL has outperformed XERS by 27.6 percentage points over the past year.
  • Xeris Biopharma is more profitable, keeping 0.2 cents of every revenue dollar as net income versus -194.9 cents for AbCellera Biologics.
  • AbCellera Biologics grew revenue faster in its latest fiscal year (+160.56% vs +43.72%).

About AbCellera Biologics

ABCL stock →

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees

About Xeris Biopharma

XERS stock →

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees

ABCL vs XERS FAQ

Which is bigger, AbCellera Biologics or Xeris Biopharma?

AbCellera Biologics (ABCL) is larger, with a market capitalization of $3.16B compared with $3.10B for Xeris Biopharma (XERS).

Which stock has performed better over the past year, ABCL or XERS?

ABCL returned +176.07% over the past 12 months, compared with +148.46% for XERS (price return, excluding dividends). Past performance does not predict future results.

Are AbCellera Biologics and Xeris Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons